
In contrast, 63 consecutive patients treated in Essen,
Germany, with TEVAR for PAU were followed up for a
mean of 46 months. In this experience, 19% required
reintervention for late endoleaks (6.3%), with the
remainder requiring reintervention secondary to disease
progression.210 A review of the outcomes captured in the
Hospital Episode Statistics database in England revealed
that 6% of patients treated for intact